Experienced in Epidermodysplasia Verruciformis

Dr. Kenneth W. Dawes

Dermatology
1601 Medical Arts Blvd, Suite 303, 
Anderson, IN 
Accepting New Patients
Offers Telehealth
Experienced in Epidermodysplasia Verruciformis
1601 Medical Arts Blvd, Suite 303, 
Anderson, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Dawes is a Dermatologist in Anderson, Indiana. Dr. Dawes is rated as an Experienced provider by MediFind in the treatment of Epidermodysplasia Verruciformis. His top areas of expertise are Neurocutaneous Melanosis, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus. Dr. Dawes is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in IN
Hospital Affiliations
Community Hospital Of Anderson And Madison County
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 25 Less Insurance Carriers -

Locations

DAWES FRETZIN DERMATOLOGY GROUP, LLC
1601 Medical Arts Blvd, Suite 303, Anderson, IN 46011

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
Enrollment Status: Completed
Publish Date: October 05, 2021
Intervention Type: Drug
Study Drug: BMX-010
Study Phase: Phase 2
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Enrollment Status: Completed
Publish Date: April 27, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

1 Total Publications

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Journal: JAMA dermatology
Published: July 20, 2022
Similar Doctors
Distinguished in Epidermodysplasia Verruciformis
Dr. Emily C. Keller
Dermatology
Distinguished in Epidermodysplasia Verruciformis
Dr. Emily C. Keller
Dermatology
8936 Southpointe Dr, Suite B2, 
Indianapolis, IN 
 (41.4 miles away)
317-215-0928
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Emily Keller is a Dermatologist in Indianapolis, Indiana. Dr. Keller is rated as a Distinguished provider by MediFind in the treatment of Epidermodysplasia Verruciformis. Her top areas of expertise are Actinic Keratosis, Sunburn, Warts, and Seborrheic Keratosis. Dr. Keller is currently accepting new patients.

Advanced in Epidermodysplasia Verruciformis
Dr. Alison S. Klenk
Dermatology
Advanced in Epidermodysplasia Verruciformis
Dr. Alison S. Klenk
Dermatology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (34.1 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alison Klenk is a Dermatologist in Indianapolis, Indiana. Dr. Klenk is rated as a Distinguished provider by MediFind in the treatment of Epidermodysplasia Verruciformis. Her top areas of expertise are Giant Congenital Melanocytic Nevus, Giant Congenital Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, and Neurocutaneous Melanosis. Dr. Klenk is currently accepting new patients.

Advanced in Epidermodysplasia Verruciformis
Dr. Drew M. Anderson
Dermatology
Advanced in Epidermodysplasia Verruciformis
Dr. Drew M. Anderson
Dermatology

Lifetime Skin Care Centers, LLC

401 W Mcgalliard Rd, 
Muncie, IN 
 (17.3 miles away)
765-288-6200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Drew Anderson is a Dermatologist in Muncie, Indiana. Dr. Anderson is rated as a Distinguished provider by MediFind in the treatment of Epidermodysplasia Verruciformis. His top areas of expertise are Actinic Keratosis, Warts, Seborrheic Keratosis, and Basal Cell Skin Cancer. Dr. Anderson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dawes's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile